Abstract:American Journal of HematologyVolume 98, Issue 5 p. E106-E109 CORRESPONDENCEFree Access Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], zhuhhd[email protected], [email protected]Search for more papers by this author De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this author First published: 15 February 2023 https://doi.org/10.1002/ajh.26877 De Zhou, Xianbo Huang and Mixue Xie contributed equally to the work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL To the Editor: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive and life-threatening disease that can be classified into primary and secondary HLH, most adult patients have secondary HLH, and the main secondary causes are infection, rheumatic disease, and malignancy. The current first-line treatment regimen such as HLH-94 or HLH-2004 are largely extrapolated from pediatric HLH; however, the prognosis of adult HLH is worse than that of children.1, 2 In addition to its unsatisfactory efficacy, the toxicity of HLH-94/HLH-2004 regimens has resulted in relatively high treatment-related mortality,2 Therefore, more efficient and less toxic induction therapy is needed in secondary HLH. Excessive production of cytokines contributes to the pathogenesis of HLH. Recent studies have indicated that ruxolitinib, a small-molecule inhibitor of Janus kinases (JAKs), which are essential for cytokine signaling, may be therapeutic in HLH. A prospective study demonstrated that ruxolitinib is effective and safe in adults with secondary HLH,3 and all patients responded to ruxolitinib and survived for more than two months. Moreover, Lauren K. Meyer et al.4 demonstrated that hypercytokinemia of HLH reduces the apoptotic potential of CD8+ T cells, leading to relative dexamethasone resistance, and this apoptotic potential is restored both in vitro and in vivo upon exposure to ruxolitinib. Based on the above studies, we performed this single-center, pilot study to evaluate the efficacy and tolerability of Ru-D in adult patients with secondary HLH at the First Affiliated Hospital, College of Medicine, Zhejiang University. Patients enrolled in this study met the following criteria: (1) fulfilled at least five of the eight HLH-2004 criteria for HLH; (2) male or female, older than 18 years; (3) no prior chemotherapy treatment for HLH; and (4) signed an informed consent form before participating in the study. Patients who met any one of the following were ineligible: central nervous system involvement, presence of a malignancy, HIV infection, and pregnant women. Patients in this study underwent an 8-week period of treatment. The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering). For follow-up and salvage treatment, we employed the following criteria: (1) If patients did not respond to the Ru-D regimen after 7 days or relapsed at any point during treatment, they entered a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP); (2) If patients were diagnosed with lymphoma after enrollment, chemotherapy was immediately started; (3) After 8 weeks of treatment, if no recurrence and no HLH-related gene mutations were detected, treatment was discontinued, and these patients entered the follow-up stage; (4) Allo-HSCT was performed in patients who met the criteria for allo-HSCT. The primary endpoint was the overall response during treatment with the Ru-D regimen in this study. The overall response rate (ORR) included the percentage of patients with a complete response (CR), a partial response (PR), or an improvement in the measures of HLH. Efficacy was evaluated 7, 14, 28, and 56 days after initiating Ru-D therapy. The efficacy of treatment was assessed according to the evaluation criteria proposed by Franco et al5 Secondary endpoints were safety and tolerability, progression-free survival (PFS), overall survival (OS), and changes in biomarkers between baseline and post-treatment. Adverse events in this study were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0). From April 1, 2021 to May 31, 2021, a total of 8 patients were enrolled in this study. The main clinical characteristics of the patients enrolled are summarized in Table 1. All the patients were adults, and the median age was 48 years (range 23–77 years). Among the 8 patients, five were eventually diagnosed with lymphoma-associated HLH (LAHS) after enrollment. The remaining three included one bacterial infection-associated HLH and two cases of Epstein–Barr virus-associated HLH (EVB-HLH). Serum EBV-DNA copies were positive in seven patients (102–106 copies/mL) and were negative in the patient who was diagnosed with bacterial infection-associated HLH. The eight patients had ECOG performance status scores of 2 to 4, and most patients were steady at 3 or 4. TABLE 1. Baseline characteristics and response of enrolled patients. Clinical features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Age(years) 37 39 54 69 76 77 42 23 Gender Female Male Male Female Female Female Female Male ECOG score 2 4 3 3 3 3 2 4 Previous therapies IVIG, antibiotics, antivirals, corticosteroid IVIG, antibiotics, corticosteroid Antibiotics, antivirals, corticosteroid Antibiotics, corticosteroid Antibiotics Antibiotics Antibiotics, corticosteroid Antibiotics, corticosteroid Etiology NKTCL Bacterial infections DLBCL PTCL EBV-HLH PTCL EBV-HLH NKTCL Fever Yes Yes Yes Yes Yes Yes Yes Yes Splenomegaly Yes No Yes Yes No No Yes Yes Absolute neutrophil count (×109/L) 1.3 12.07 4.76 0.8 1.7 0.5 0.9 0.6 Hemoglobin concentration (g/L) 77 113 121 82 89 124 81 92 Absolute platelet count (×109/L) 32 282 81 89 67 23 31 3 Triglyceride concentration (mmol/L) 3.14 1.94 2.03 1.06 1.25 3.38 2.31 4.43 Fibrinogen concentration (g/L) 1.05 3.67 6.78 0.96 1.48 1.8 0.5 1.28 Ferritin concentration (μg/L) 1151.8 19176.6 4222.6 2299.4 32847.2 20241.4 5156.3 >40 000 Hemophagocytosis in bone marrow Yes Yes No No Yes Yes Yes Yes Natural killer cell activity (%) 21.05 6.95 14.84 — — — 16.44 14.48 Natural killer cell CD107a (%) 10.44 0.99 3.49 — — — 4.56 1.52 Soluble CD25 (pg/mL) 58 240 20 917 78 770 — — — 13 437 43 403 HLH-2004 criteria 7/8 6/8 5/8 5/8a 5/8a 5/8a 7/8 8/8 EBV-DNA (copies/mL) 3.29 × 106 Negative 9.20 × 102 2.58 × 103 1.23 × 103 9.34 × 102 3.31 × 103 9.47 × 106 Treatment days 26 56 14 52 56 20 56 2 Best Response PR CR Improvement in measures of HLH CR CR PR CR NR Duration of Response (days) 26 269 141 52 244 20 234 — Survival No Yes No No Yes No Yes No Survival time (days) 175 450 141 332 425 20 415 2 Reason for death Progression of lymphoma — CRPA infection Relapse of lymphoma — Bronchiectasis with massive hemoptysis — Progression of HLH Note: Normal reference range: Ferritin concentration < 500 μg/L, Triglyceride concentration 1.70 < mmol/L, Fibrinogen concentration 2.0 ~ 4.0 g/L, soluble CD25 ≤ 6400 pg/mL, soluble CD163 88 ~ 902 pg/mL, Natural killer cell activity≥15.11%, Natural killer cell CD107a ≥ 10%. Abbreviations: CR, complete response; CRPA, carbapenem-resistant pseudomonas aeruginosa; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; IVIG, intravenous immunoglobulin; NKTCL, NK/T-cell lymphoma; NR, no response; PTCL, peripheral T-cell lymphoma. a Natural killer cell activity and Soluble CD25 were not tested. Patients were followed up until June 30, 2022 or until death, with none lost to follow-up. Table 1 also shows the response outcomes in detail. The median follow-up time was 8.5 (range, 0.1–15.0) months. The ORR to the Ru-D regime was 87.5% (7/8), with 50% (4/8) showing CR, 25.0% (2/8) PR, and 12.5% (1/8) improvement in measures of HLH, 12.5% (1/8) no response (NR). Among the LAHS patients, one patient (20%) achieved CR, two patients (40%) achieved PR, and 1 patient (20%) achieved improvement in measures of HLH, and 1 patient (20%) NR. All the 3 non-LAHS patients achieved CR, and no recurrence has occurred so far. The OS was 75% (6/8) at 2 months, 50% (4/8) at 6 months and 37.5% at 12 months. Although the overall mortality rate was 62.5% (5/8), there was only one death directly related to HLH. The Ru-D treatment in our study was well tolerated, with no toxicities leading to dose reduction or discontinuation of treatment observed. Ruxolitinib has been reported to have a risk of hematological toxicity, which is difficult to evaluate because cytopenia is also the major clinical feature of HLH. We found that only 1 patient (12.5%) had grade III anemia during Ru-D therapy. Four additional patients (50%) developed grade II hematologic toxicity. Regarding infections, pneumocystis pneumonia (PCP) occurred in Patient 7 after 56 days of Ru-D treatment and was successfully cured by trimethoprim-sulfamethoxazole. Patient 6 had a history of baseline bronchiectasis and chronic pulmonary infection with PA before receiving Ru-D. During treatment, this patient suffered aggravation of pulmonary infection and presented with cough, sputum, and inflammatory exudation changes on lung imaging and positive sputum culture for PA, while the body temperature remained within normal limits. She was treated with cefoperazone-sulbactam against PA but had poor control of the infection, developed massive hemoptysis on Day 19, and died in 48 hours. For other patients, no unusual infections were observed. Secondary HLH in adults is a major clinical challenge due to its rapid progression and high mortality. The current first-line treatment strategies are the HLH-94 and HLH-2004 regimens, the ORR was approximately 70%. There were 8 patients enrolled in our study, whose ORR was 87.5%, which is higher than the patients treated with the HLH-94/HLH-2004 regimen. The survival of adult patients with HLH is poor, in a large, multicenter, retrospective study, the median OS in patients with malignancy-associated HLH was 2.8 months and for those with non-malignancy-associated HLH was 10.7 months.3 We also have retrospectively analyzed 205 patients seen between January 2011 and December 2015 in our hospital. The median OS was only 1.8 months, and most of these patients received HLH-94 as initial treatment.6 In this study, the median OS was 4.7 months in patients with LAHS, and all the patients with non-LAHS are now alive with a CR status for more than one year. In contrast to the above studies, this study demonstrated better short-term survival in both malignancy-associated HLH and non-malignancy-associated HLH patients. In our study, Ru-D regimen shows that it is an efficient and safe initial treatment for patients with LAHS, the rapid control of cytokine-driven inflammation gives these patients opportunity to confirm the diagnosis of lymphoma and bridge to chemotherapy. Although Ru-D regimen may improve short-term survival in LAHS patients, their long-term survival remains poor. More effective anti-lymphoma strategies may be the fundamental way to improve the prognosis of these patients. Overall, the Ru-P regimen was well tolerated in this study. Regarding hematologic toxicity, only 1 patient (25%) developed grade III hematologic toxicity. The peripheral blood cell counts of patients who responded gradually improved during Ru-D treatment. However, it should be noted that during Ru-D treatment, we found 2 cases of grade III or higher infection-related AE. Therefore, during Ru-D treatment, we should be aware of the aggravation of the original infection and new opportunistic infections. More experience is needed to assess the need for prophylactic anti-infective therapy in these patients. In summary, this study was a preliminary attempt at giving the Ru-D regimen to newly diagnosed adult HLH patients. Although the sample size was small and the follow-up time was relatively short. Given the rarity and high short-term mortality of adult HLH, the results of this study have some relevance indeed. Ru-D showed a high ORR and good safety and has the potential to become a first-line treatment for HLH in adults. AUTHOR CONTRIBUTIONS De Zhou, Honghu Zhu, Jie Jin, Xiujin Ye, and Xianbo Huang designed the study; De Zhou, Xianbo Huang, and Mixue Xie analyzed the results; De Zhou and Xianbo Huang wrote the paper; De Zhou, Xiu jin Ye, Xianbo Huang, and Xueying Li performed the research; Xin Huang, Xiudi Yang, Li LI, Lixia Zhu, Jingjing Zhu, Xiaolong Zheng, Jianai Sun, Shuqi Zhao, Wenjuan Yu, Wanzhuo Xie, and Hongyan Tong collected the data and reviewed the paper. De Zhou, Xiujin Ye, and Xianbo Huang obtained funding. Honghu Zhu and Jie Jin provided administrative support. All authors read and approved the final manuscript. ACKNOWLEDGMENTS The authors thank the patients and their families, and medical staff who participated in this study. This work was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LGF22H160040 and LZ22H080002), and Natural Science Foundation of China (No. 81900152). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016; 172: 412- 419. 2Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100: 2367- 2373. 3Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-Centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. 4Meyer LK, Verbist KC, Albeituni S, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020; 136(6): 657- 668. 5Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19): 1811- 1822. 6Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. Int J Med. 2018; 111: 23- 31. Volume98, Issue5May 2023Pages E106-E109 ReferencesRelatedInformation

Abstract:Clinical and Translational MedicineVolume 13, Issue 2 e1109 LETTER TO THE EDITOROpen Access A novel autophagy activator ginsenoside Rh2 enhances the efficacy of immunogenic chemotherapy Jing Yang, Jing Yang Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorWei Zhang, Wei Zhang Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorLin Jia, Lin Jia College of Pharmacy, Shenzhen Technology University, Shenzhen, ChinaSearch for more papers by this authorFei Shi, Fei Shi Emergency Department, Institute of Shenzhen Respiratory Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorMin Cao, Min Cao Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorJichao Sun, Jichao Sun Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorChengchao Xu, Chengchao Xu Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorZhijie Li, Zhijie Li Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorZhiqiang Cheng, Corresponding Author Zhiqiang Cheng [email protected] Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China Correspondence Chuanbin Yang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. Email: [email protected] Jigang Wang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; Artemisinin Research Center, Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700 China. Email: [email protected] Shan-Chao Zhao, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510500 China. Email: [email protected] Zhiqiang Cheng, Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology) Email: [email protected]Search for more papers by this authorShan-Chao Zhao, Corresponding Author Shan-Chao Zhao [email protected] Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China Correspondence Chuanbin Yang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. Email: [email protected] Jigang Wang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; Artemisinin Research Center, Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700 China. Email: [email protected] Shan-Chao Zhao, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510500 China. Email: [email protected] Zhiqiang Cheng, Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology) Email: [email protected]Search for more papers by this authorJigang Wang, Corresponding Author Jigang Wang [email protected] orcid.org/0000-0002-0575-0105 Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China Correspondence Chuanbin Yang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. Email: [email protected] Jigang Wang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; Artemisinin Research Center, Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700 China. Email: [email protected] Shan-Chao Zhao, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510500 China. Email: [email protected] Zhiqiang Cheng, Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology) Email: [email protected]Search for more papers by this authorChuanbin Yang, Corresponding Author Chuanbin Yang [email protected] orcid.org/0000-0001-8288-4038 Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China Correspondence Chuanbin Yang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. Email: [email protected] Jigang Wang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; Artemisinin Research Center, Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700 China. Email: [email protected] Shan-Chao Zhao, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510500 China. Email: [email protected] Zhiqiang Cheng, Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology) Email: [email protected]Search for more papers by this author Jing Yang, Jing Yang Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorWei Zhang, Wei Zhang Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorLin Jia, Lin Jia College of Pharmacy, Shenzhen Technology University, Shenzhen, ChinaSearch for more papers by this authorFei Shi, Fei Shi Emergency Department, Institute of Shenzhen Respiratory Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorMin Cao, Min Cao Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorJichao Sun, Jichao Sun Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorChengchao Xu, Chengchao Xu Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorZhijie Li, Zhijie Li Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, ChinaSearch for more papers by this authorZhiqiang Cheng, Corresponding Author Zhiqiang Cheng [email protected] Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China Correspondence Chuanbin Yang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. Email: [email protected] Jigang Wang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; Artemisinin Research Center, Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700 China. Email: [email protected] Shan-Chao Zhao, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510500 China. Email: [email protected] Zhiqiang Cheng, Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology) Email: [email protected]Search for more papers by this authorShan-Chao Zhao, Corresponding Author Shan-Chao Zhao [email protected] Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China Correspondence Chuanbin Yang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. Email: [email protected] Jigang Wang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; Artemisinin Research Center, Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700 China. Email: [email protected] Shan-Chao Zhao, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510500 China. Email: [email protected] Zhiqiang Cheng, Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology) Email: [email protected]Search for more papers by this authorJigang Wang, Corresponding Author Jigang Wang [email protected] orcid.org/0000-0002-0575-0105 Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China Correspondence Chuanbin Yang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. Email: [email protected] Jigang Wang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; Artemisinin Research Center, Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700 China. Email: [email protected] Shan-Chao Zhao, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510500 China. Email: [email protected] Zhiqiang Cheng, Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology) Email: [email protected]Search for more papers by this authorChuanbin Yang, Corresponding Author Chuanbin Yang [email protected] orcid.org/0000-0001-8288-4038 Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China Correspondence Chuanbin Yang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China. Email: [email protected] Jigang Wang, Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China; Artemisinin Research Center, Institute of Chinese Materia Medica, Chinese Academy of Chinese Medical Sciences, Beijing, 100700 China. Email: [email protected] Shan-Chao Zhao, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510500 China. Email: [email protected] Zhiqiang Cheng, Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology) Email: [email protected]Search for more papers by this author First published: 02 February 2023 https://doi.org/10.1002/ctm2.1109Citations: 1 Jing Yang, Wei Zhang, Lin Jia and Fei Shi contributed equally to this work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Dear Editor, Immunogenic cell death (ICD) caused by certain chemotherapeutic drugs, including mitoxantrone (MTX), elicits specific protective anti-tumour immunity and is, thus, regarded as an effective strategy for cancer treatment. Pharmacological enhancement of autophagy is effective in enhancing anticancer immune responses to ICD-inducing chemotherapeutic drugs. Here, we discover that ginsenoside Rh2 (G-Rh2) enhance MTX-induced hallmarks of ICD, which include increased ATP release, relocation of calreticulin (CALR) to the cell membrane and HMGB1 (high mobility group box 1) secretion. Mechanistic studies reveal that G-Rh2induces autophagy through the activation of TFEB (transcription factor EB) and TFE3 (transcription factor E3), which contributes to the synergistic effect of G-Rh2 and MTX on promoting ATP release. In addition, G-Rh2 increased endoplasmic reticulum (ER) stress with phosphorylated eukaryotic initiation factor eIF2α, which promoted MTX-induced cell surface calcineurin exposure. Consequently, G-Rh2 enhanced the in vivo anti-tumour effect of MTX in immunocompetent mice bearing MCA205 tumour with increased cytotoxic T lymphocytes (CTLs). Thus, G-Rh2 represents a promising drug candidate for treating cancers in combination with ICD-inducing chemoimmunotherapeutic drugs such as MTX. In response to certain cellular stimuli, injured or stressed cells release DAMPs on their surface to produce immunostimulatory effects, including recruiting and activating immune cells that ultimately kill cancer cells.1 This kind of regulated cell death is referred to as ICD.1, 2 ICD can be triggered by multiple chemotherapeutics such as oxaliplatin and MTX. Key hallmarks of ICD include the secretion of ATP, cell surface relocation of CALR and extracellular release of HMGB1.2 Extracellular ATP acts as a ‘find me’ molecule that recruits antigen-presenting cells to promote anticancer immunity. Cell membrane CALR acts as an ‘eat me’ molecule for dendritic cells (DCs) to capture antigens and trigger tumour-specific cytotoxic T-cell responses. Extracellular HMGB1 binds to its receptor such as TLR4 on DCs, which promotes tumour antigen processing and presentation to T cells. Thus, the induction of ICD triggers long-lasting anti-tumour immunity, and it is regarded as an effective strategy for cancer treatment.2, 3 TFEB and TFE3 are key transcription factors that regulate autophagy.4, 5 With respect to ICD, the activation of several stress pathways, including autophagy, is indispensable for intracellular ATP release.6 Induction of autophagy by several ICD inducers enhances the anticancer effects via modulating the tumour microenvironment.7 Therefore, autophagy activation to enhance the effects of chemotherapeutics on inducing ICD holds promise for anticancer therapy.8 Driven by these considerations, we sought to identify novel autophagy enhancer(s) and evaluate their roles in stimulating anticancer immunity in combination with ICD-inducing chemotherapeutics in U2OS cells (human bone osteosarcoma epithelial cells), MCA205 cells (mouse fibrosarcoma cells) and MCA205-inoculated immunocompetent mice. Here, we found that G-Rh2 upregulated the autophagy marker LC3-II levels (Figure 1A), and lysosomal inhibitor CQ further enhanced LC3-II levels (Figure 1B,C). Immunostaining results further showed that G-Rh2 increased autophagosomes and autolysosomes (Figure 1D–G). These results indicate that G-Rh2 promotes autophagy. Furthermore, G-Rh2 enhanced the nuclear accumulation of TFEB and TFE3 as reflected by immunofluorescence (Figures 1H,I and S1A,C) and western blotting (Figure S1B,D). Knock-down of the expression of both TFEB and TFE3 (Figure S1E–H, Table S1) inhibited G-Rh2-induced autophagic flux (Figure S1I). Furthermore, G-Rh2 promoted TFEB dephosphorylation (Figure S1J), and the nuclear accumulation of TFEB/TFE3 is earlier than autophagy induction (Figure S1K,L). These results suggest that G-Rh2 enhances autophagy via TFE3 and TFEB. FIGURE 1Open in figure viewerPowerPoint Ginsenoside Rh2 (G-Rh2) induces autophagy via transcription factor EB (TFEB) and transcription factor E3 (TFE3) activation: (A) G-Rh2 increases LC3-II levels. U2OS cells were exposed to different doses of G-Rh2 (1, 5 and 10 μM) for 16 h, and LC3-II was measured; (B and C) G-Rh2 induces autophagic flux. U2OS cells were exposed to G-Rh2 (10 μM) with or without CQ (50 μM, added at last for 3 h) for 16 h, LC3-II was measured (B) and quantified by ImageJ (C); (D and E) G-Rh2 increases LC3 puncta. After treating U2OS cells transiently expressing GFP-LC3 with G-Rh2 for 16 h, LC3 puncta was visualized (D) and quantified (E); (F and G) G-Rh2 increases autolysosomes. After treating U2OS cells transiently expressing GFP-RFP-LC3 with G-Rh2 (10 μM) for 16 h, LC3 puncta was recorded (F) and red-only puncta (autolysosome) was quantified (G). Scale bar: 15 μm; (H and I) G-Rh2 induces the relocation of TFEB and TFE3 from the cytoplasm into the nucleus. U2OS cells transiently expressing 3XFlag-TFEB or GFP-N1-TFE3 were incubated with indicated doses of G-Rh2 (1, 5 and 10 μM) for 16 h. The distribution of TFEB in cells was detected by fluorescence microscope. Scale bar: 15 μm. *p < .05; **p < .01 We further determined whether G-Rh2 induces hallmarks of ICD with or without a low concentration of MTX (MTXlow). G-Rh2 or MTX slightly but significantly reduced intracellular ATP release, and G-Rh2 combined with MTXlow substantially reduced the intracellular ATP contents (Figure 2A,B). Autophagy deficiency by knocking down ATG5 (Figure 2C–E) attenuated G-Rh2 plus MTXlow-induced decrease in intracellular ATP contents as reflected by quinacrine staining (Figure 2F)9 and the release of extracellular ATP contents (Figure 2G). Similarly, the combination of G-Rh2 and MTX-induced decrease of intracellular ATP and increase of extracellular ATP was inhibited in TFE3- and TFEB-knocked-down cells (Figure 2H,I). These findings demonstrate that the synergistic effect of G-Rh2 and MTX on ATP release depends on autophagy induction. FIGURE 2Open in figure viewerPowerPoint Ginsenoside Rh2 (G-Rh2) enhances autophagy-dependent ATP release: (A) G-Rh2 reduces intracellular ATP contents. U2OS cells were exposed to vehicle control, G-Rh2 (10 μM), a low dose of MTXlow (1 μM) or their combination for 16 h. The intracellular ATP contents were examined by quinacrine staining. MTXhigh (5 μM) was used as a positive control. Scale bar: 15 μm; (B) quantification data in (A) shows that G-Rh2 promotes mitoxantrone (MTX)-induced reduction of intracellular ATP contents; (C–E) after transfected U2OS cells with siRNA to knock down the expression of key autophagy gene ATG5, ATG5 and LC3-II levels were measured (C) and quantified (D and E); (F and G) the inhibition of autophagy through knocking down of the expression of ATG5 attenuates G-Rh2 plus MTX-induced ATP release. After ATG5 knocking down, U2OS cells were treated with vehicle control, G-Rh2 (10 μM), MTXlow (1 μM) or the combination of G-Rh2 (10 μM) and MTXlow (1 μM) for 16 h, the intracellular ATP levels were measured by quinacrine staining (F) and the extracellular ATP contents were measured by a bioluminescent assay kit (G); (H and I) inhibition of autophagy by transcription factor EB (TFEB)/transcription factor E3 (TFE3) knockdown attenuates G-Rh2 plus MTX-induced ATP release. After TFE3 and TFEB knockdown, U2OS cells were incubated with G-Rh2, MTXlow, or the combination of G-Rh2 (10 μM) and MTXlow (1 μM) for 16 h, and the intracellular ATP contents were measured by quinacrine staining (H), and the extracellular ATP contents were measured by a bioluminescent assay kit (I). Scale bar: 15 μm. *p < .05, **p < .01 Furthermore, G-Rh2 increased MTXlow-induced cell surface exposure of CALR as reflected by immunostaining and flow cytometry analysis (Figures 3A–C and S2A,B). The combination of G-Rh2 and MTXlow also increased an HMGB1 release (Figure 3D–G). To determine how G-Rh2 and MTX induce cell surface CALR exposure, we next showed that G-Rh2 increased ER stress, especially PERK/p-eIF2α/ATF4 axis (Figure S3A–H). We discovered that PERK knock-down reduced G-Rh2-induced ER stress (Figure S3I–K) and comprised G-Rh2 plus MTX-caused cell surface CALR exposure (Figure 3H,I). Interestingly, the inhibition of ER stress by 4-PBA (4-phenylbutyric acid) also attenuated cell surface relocation of CALR (Figure S3L). These results indicate that ER stress is indispensable for the role of G-Rh2 in enhancing MTX-induced cell surface relocation of CALR. Apart from ICD, the combination of G-Rh2 and MTX also induced cell apoptosis, and this effect was further enhanced by the lysosomal inhibitor CQ (Figure S4A,B), suggesting that the apoptosis may also be involved in anticancer effects. To understand the crosstalk of autophagy and ER stress during ICD, we found that the inhibition of lysosomal functions by CQ did not further enhance ER stress (Figure S4C), and ER stress inhibitor 4-PBA attenuated autophagy in response to G-Rh2 (Figure S4D). Consistently, CQ did not enhance G-Rh2 plus MTX-induced cell surface CALR exposure (Figure S4E) but attenuated G-Rh2 plus MTX-induced ATP release (Figure S4F), supporting a critical role of autophagy in promoting ATP release. Furthermore, though apoptosis inhibitor Z-VAD-FMK inhibits G-Rh2 plus MTX-induced apoptosis (Figure S5B), Z-VAD-FMK did not inhibit G-Rh2 plus reduction of intracellular ATP levels (Figure S5A), and cell surface CALR exposure (Figure S5C,D), further strengthen the hypothesis that ICD rather than apoptosis is involved in the anti-tumour effect of G-Rh2 plus MTX. FIGURE 3Open in figure viewerPowerPoint Ginsenoside Rh2 (G-Rh2) enhances the cell surface exposure of calreticulin (CALR) and the release of HMGB1 (high mobility group box 1) in the presence of mitoxantrone (MTX): (A) G-Rh2 enhances MTX-induced cell surface relocation of CALR. U2OS cells transiently expressing CALR-KDEL-RFP were treated with a low concentration of MTXlow (1 μM) with or without G-Rh2 (10 μM) for 16 h. The cell surface CALR was visualized by a confocal microscope. MTXhigh (5 μM) was used as a positive control. Scale bar: 15 μm; (B) quantification of cell surface CALR exposure in (A); (C) G-Rh2 enhances MTX-induced cell surface CALR exposure measured by flow cytometry. After drug treatment as shown in (A), U2OS cells were collected for the detection of endogenous CALR exposure via flow cytometry; (D–G) G-Rh2 enhances MTX-induced HMGB1 release. Intracellular HMGB1 was detected by immunostaining after drug treatment for 24 h (D) and quantified (E). Extracellular HMGB1 contents in cell culture medium were detected by western blotting after drug treatment (F) and quantified (G). Briefly, an equal amount of cell culture medium was precipitated using trichloroacetic acid followed by western blotting analysis. Scale bar: 15 μm; (H and I) inhibition of endoplasmic reticulum (ER) stress by knocking down of PERK, a key molecule in ER stress, attenuates G-Rh2-induced cell surface CALR exposure as determined by flow cytometry. *p < .05; **p < .01 To confirm the conserved synergistic effects of G-Rh2 and MTX in enhancing ICD, we showed that in immunosurveillance MCA205 mouse fibrosarcoma cells, G-Rh2 also enhanced autophagy (Figure S6A), induced ER stress (Figure S6B,C). Consistently, G-Rh2 enhanced MTXlow-induced cell surface CALR exposure, HMGB1 release from the nucleus, and extracellular ATP release (Figure S6D–I), suggesting that G-Rh2 also promotes MTX-induced ICD in MCA205 fibrosarcoma cells. MCA205 cells inoculated in mice are well characterized as a suitable model for the investigation of immune response, and the tumour infiltration on the skin can also be considered to be orthotopic.10 We next determined the synergistic anti-tumour role of G-Rh2 in combination with MTX by inoculating MCA205 cells into immunocompetent C57 mice followed by drug treatment as shown in the schematic model (Figure 4A). We showed that G-Rh2, MTX and a combination of G-Rh2 and MTX did not affect mice's body weight (Figure 4B), but the combination treatment significantly mitigated tumour growth (Figure 4C,D). Importantly, the combination treatment increased the abundance of CTLs while exerting minimal effect on that of regulatory T cells (Tregs) (Figures 4E,F and S7). Consequently, this combination treatment increased the CTL/Treg ratio (Figure 4G), suggesting that G-Rh2 and MTX synergistically promote anti-tumour immunity by tipping the immune balance and reprogramming the tumour microenvironment. FIGURE 4Open in figure viewerPowerPoint Ginsenoside Rh2 (G-Rh2) promotes the efficacy of anticancer chemotherapy in mice: (A) schematic diagram of drug treatment in MCA205 mouse fibrosarcomas-bearing mice. When tumours became palpable, mice received systemic intraperitoneal injection of G-Rh2, mitoxantrone (MTX) alone or their combination. At least seven mice per group; (B) treatment of mice with G-Rh2, MTX alone or their combination does not affect mice's body weight; (C and D) G-Rh2 plus MTX treatment significantly inhibits tumour growth (C) and reduces tumour size (D) of MCA205 fibrosarcomas in mice; (E) G-Rh2 plus MTX increases the ratio of CD3+CD8+ cytotoxic T lymphocytes (CTLs); (F) treatment of mice with G-Rh2, MTX alone or in combination does not affect the ratio of CD4+ FOXP3+ Treg cells; (G) treatment of mice with the combination of G-Rh2 and MTX increases the ratio of CD3+ CD8+ T lymphocytes over Treg cells; *p < .05; **p < .01. (H) a schematic model illustrating the effects of G-Rh2 in enhancing MTX-induced immunogenic cell death (ICD) and promoting its anti-tumour effects via reprogramming the tumour microenvironment. G-Rh2 enhances MTX-induced hallmarks of ICD, such as ATP release, cell surface calreticulin (CALR) exposure and HMGB1 (high mobility group box 1) release. Mechanistically, G-Rh2 promotes MTX-induced ATP release via transcription factor EB (TFEB)/transcription factor E3 (TFE3)-mediated autophagy, and G-Rh2 facilitates MTX-induced cell surface CALR exposure via activating endoplasmic reticulum (ER) stress through PERK/p-eIF2α/ATF4 axis. As such, G-Rh2 synergizes with MTX to increase the abundance of CTLs in tumours, which ultimately promotes the in vivo anti-tumour effects of chemotherapeutic ICD-inducer MTX. Overall, this study illustrates that G-Rh2 is responsible for TFE3/TFEB-mediated autophagy activation and ER-stress induction with phosphorylated eIF2α, and it synergizes with immunogenic chemotherapeutic drug MTX to enhance MTX-induced ICD, which consequently facilitates the anti-tumour effect of MTX in immunocompetent mice in vivo (Figure 4G). Our findings provide mechanistic insights into how G-Rh2 synergizes with MTX to amplify its effects on ICD induction and anti-tumour activity and provide a novel link between G-Rh2-activated TFEB/TFE3-dependent autophagy induction and ICD-involved anti-tumour effect. Our discovery indicates that G-Rh2 is a novel drug candidate for improving the anti-tumour effects of immunogenic chemotherapies. ACKNOWLEDGEMENTS This work was supported by the National Natural Science Foundation of China (81902787, 82003721, 82074098, 82274182, 81841001), National Key Research and Development Program of China (2020YFA0908000), Shenzhen Science and Technology Innovation Commission (JCYJ20210324114014039, JCYJ20210324115800001), China Postdoctoral Science Foundation (2020M683182) and Guangdong Basic and Applied Basic Research Foundation (2020A1515110549). CONFLICTS OF INTEREST There are no conflicts of interest between all authors. Open Research DATA AVAILABILITY STATEMENT Data are available on reasonable request from the authors. Supporting Information Filename Description ctm21109-sup-0001-Figures.docx3.3 MB Figures ctm21109-sup-0002-SuppMat.docx50.6 KB Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019; 23: 4854- 4865. 2Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022; 23: 487- 500. 3Xia H, Green DR, Zou W. Autophagy in tumour immunity and therapy. Nat Rev Cancer. 2021; 21: 281- 297. 4Zhang W, Xu C, Sun J, Shen H-M, Wang J, Yang C. Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: pathogenic mechanisms and therapeutic potential. Acta Pharm Sin B. 2022; 12: 1019- 1040. 5Yang C, Su C, Iyaswamy A, et al. Celastrol enhances transcription factor EB (TFEB)-mediated autophagy and mitigates Tau pathology: implications for Alzheimer's disease therapy. Acta Pharm Sin B. 2022; 12: 1707- 1722. 6Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011; 334: 1573- 1577. 7Pietrocola F, Pol J, Vacchelli E, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016; 30: 147- 160. 8Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 2019; 9: 1167- 1181. 9Liu P, Zhao L, Pol J, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun. 2019; 10: 1486. 10Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016; 16: 759- 773. Volume13, Issue2February 2023e1109 FiguresReferencesRelatedInformation

The Necessity of Studying Antibiotic Duration in Acute Leukemia Patients with Pseudomonas Aeruginosa Bloodstream Infection: A Response to Terada and Kanno

The Study Design and Methodology of Antibiotic Duration in Hematological Patients with Pseudomonas Aeruginosa Bloodstream Infection.

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study

An Optimized Integrin Α6‐targeted Peptide for Positron Emission Tomography/magnetic Resonance Imaging of Pancreatic Cancer and Its Precancerous Lesion

The Concentrated Antibody from Convalescent Plasma Balanced the Dysfunctional Immune Responses in Patients with Critical COVID‐19

Prognostic Value of Post-Transplantation Wilms' Tumor Gene 1 Expression in Acute Myeloid Leukaemia Subgroup According to Different Pre-Transplant Disease Status

Identification and Lineage Restriction Analyses of Preleukemia Cells in a Sporadic Biallelic CEBPA Mutated Acute Myeloid Leukemia Patient

Persistent Viral Activity, Cytokine Storm, and Lung Fibrosis in a Case of Severe COVID‐19

Ott_a_280535 12163..12168

Efficacy of Rituximab for Patients with Anti-Glomerular Basement Membrane Disease.

Long‐term Outcomes of Relapsed/refractory Double‐hit Lymphoma (r/r DHL) Treated with CD19/22 CAR T‐cell Cocktail Therapy

Fear of Disease Progression and Psychological Stress in Cancer Patients under the Outbreak of COVID‐19

Anaplastic Lymphoma Kinase Positive Histiocytosis Presenting As Hemocytopenia in an Infant

Resveratrol Inhibits the Replication of Severe Acute Respiratory Syndrome Coronavirus 2 (sars‐cov‐2) in Cultured Vero Cells

Enhancing Neurosyphilis Diagnosis: Evaluating Novel Biomarkers and Clinical Implementation Challenges

Cohort Profile: the Northeast China Biobank (Nec-Biobank)

A Novel Autophagy Activator Ginsenoside Rh2 Enhances the Efficacy of Immunogenic Chemotherapy

Clinical Characteristics of Two Patients with Α1‐antitrypsin Pittsburgh in a Chinese Family

Sex-specific Characteristics and Outcomes in Hospitalized Heart Failure with Preserved Ejection Fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.

Influence of COVID‐19 in Patients with Concurrent Tuberculosis Coinfections